Variance in CD16 affinity for Fc IgG, CD16 polymorphism, and varying expression of CD16 on tumor-infiltrating lymphocytes also remain a challenge, perhaps to be overcome by Fc glyco-optimization and targeting alternative activating receptors on the NK cell surface, such as NKp46. This evidence concerns the gene FCGR3A and neoplasm.